21 October 2022 | Other

Immune response from Moderna's updated Omicron vaccine persists for 3 months

Moderna Inc's COVID-19 booster vaccine, aimed at the BA.1 Omicron strain, elicits a powerful immune reaction against this subvariant, keeping antibodies at a high level for at least three months, as reported by the company.

The vaccine developed by Moderna against the Omicron variant has already received regulatory approval in a number of countries.

Stephane Bancel, Chief Executive Officer of Moderna Inc, said that clinical trials have shown an excellent immune response, which has been achieved with the help of a bivalent booster and retains its effect for at least 3 months.

The company also noted that the data regarding the trials of its target vaccine BA.4/BA.5 in humans are expected later this year.

Company MarketCheese
Expectation: 1250 pips
Selling USDJPY with 146.450 target while anticipating BoJ rate decision
Today at 06:40 AM 35
Period: 17.09.2025 Expectation: 500 pips
Buying SPX on 0.5% Fed rate cut
Yesterday at 11:38 AM 176
Period: 24.09.2025 Expectation: 1500 pips
USDCAD is set to fall ahead of interest rate decisions
Yesterday at 10:57 AM 158
Period: 23.09.2025 Expectation: 500 pips
NVIDIA shares approach gap closure at $170.50
Yesterday at 10:26 AM 140
Period: 31.12.2025 Expectation: 200 pips
Buying NVIDIA shares with $195 in view
Yesterday at 08:54 AM 38
Period: 24.09.2025 Expectation: 1300 pips
EURUSD is expected to correct after Fed announces rate decision
Yesterday at 07:14 AM 163
Go to forecasts